Description
A PCSK9 inhibitor; increases LDLR levels in HepG2 cells expressing PCSK9 at 400 nM; reduces plasma total cholesterol levels by a mean of 38% in mice fed a high-fat diet at 8 mg/kg per day; reduces plasma LDL cholesterol levels in mice fed a high-fat diet and exhibits an additive effect when administered in combination with atorvastatin,,
Formal name: N-[4-[[4-(4-methylphenyl)-2-phenyl-1-piperazinyl]carbonyl]phenyl]-acetamide
Synonyms:
Molecular weight: 413.5
CAS: 1629166-02-4
Purity: ≥98%
Formulation: A crystalline solid
Product Type|Biochemicals|Small Molecule Inhibitors|Peptidases & Proteases||Research Area|Cardiovascular System|Lipids & Lipoproteins||Research Area|Cell Biology|Proteolysis|Cytosolic & Secreted Proteases||Research Area|Endocrinology & Metabolism|Metabolic Diseases|Dyslipidemias
